Drug Trial Radar · NCT07868926
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Oct 16, 2026
Primary completion
Dec 15, 2026
Study completion Dec 15, 2026
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.
Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
14C-VX-407Drug
Solution for Oral Administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amount of Radioactivity Excreted (Ae) of 14C-VX-407 Total Radioactivity (TRA) in Urine, and FecesTime frame: From Day -1 up to Day 30
- Terminal Phase Rate Constant (λz) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
- Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
- Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
- Apparent Clearance (CL/F) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
- Renal Clearance (CLr) of VX-407Time frame: From Day -1 up to Day 30
- Maximum Observed Plasma Concentration (Cmax) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
- Time for VX-407 to Reach Maximum Concentration (Tmax) of VX-407 in Plasma and UrineTime frame: From Day 1 up to Day 30
- Fraction (percent) of Dose Excreted Unchanged in Urine of VX-407 (fe)Time frame: From Day -1 up to Day 30
- Apparent Volume of Distribution (Vz/F) (Based on the Terminal Phase) of VX-407 in PlasmaTime frame: From Day 1 up to Day 30
- Terminal Phase Rate Constant (λz) of Total Radioactivity (TRA) in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
- AUC0-tlast of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
- AUC0-inf of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
- CL/F of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
- Cmax of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
- Fraction (percent) of Dose Excreted Unchanged in Urine of TRATime frame: From Day -1 up to Day 30
- Apparent Volume of Distribution (Based on the Terminal Phase) of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 30
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion - Lincoln
Lincoln, Nebraska · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.